• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2019
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2019
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Mattingly, T.J.
    II
    Slejko, J.F.
    Onukwugha, E.
    Perfetto, E.M.
    Kottilil, S.
    Mullins, C.D.
    Date
    2019
    Journal
    PharmacoEconomics
    Publisher
    Adis
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1007/s40273-019-00864-8
    Abstract
    Background: Innovations in hepatitis C virus (HCV) therapy included in traditional comparative evaluations focus on sustained virologic response (SVR) without addressing challenges patients report beyond virologic cure. This study aims to evaluate the cost-effectiveness of HCV drug therapy with a patient-centered approach. Methods: An individual-based Markov model was constructed using guidance from a stakeholder advisory board (SAB), a patient Delphi panel, and published literature to evaluate direct-acting antivirals (DAAs) compared to no treatment. The United States (US) health sector and societal perspectives were considered for 10- and 20-year time horizons. Inputs for treatment costs and effectiveness reflect a generic regimen. Indirect costs used for the societal model included estimates from self-reported productivity in a matched-control sample. Beyond the traditional quality-adjusted life-year (QALY) health outcome, this study included two novel measures developed from the Delphi panel and SAB: infected life-years and workdays missed. All costs were measured in 2018 US dollars. Results: Health sector costs and QALYs were higher in the treatment group in both 10- and 20-year models. Total infected life-years and workdays missed were reduced in the treatment group for both models. When costs of absenteeism, presenteeism, and patient/caregiver time were included, the DAA intervention was cost-saving at both 10 and 20 years. Health sector results were sensitive to drug costs and utility estimates for post-SVR health states. Societal results were sensitive to presenteeism estimates and drug costs. Conclusion: Treatment was cost-effective from a health sector perspective and cost-saving when including non-health costs such as patient/caregiver time and productivity. Copyright 2019, The Author(s).
    Sponsors
    Patient-Centered Outcomes Research Institute: 7709720-A; National Health and Medical Research Council; Takeda Pharmaceuticals North America; Novartis Pharmaceuticals Corporation; Pfizer; Pharmaceutical Research and Manufacturers of America Foundation.
    Keyword
    patient-centered economic model
    Cost-Benefit Analysis
    Hepatitis C, Chronic--drug therapy
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076764805&doi=10.1007%2fs40273-019-00864-8&partnerID=40&md5=ec2acb1b56d673e456eba333de90bd76; http://hdl.handle.net/10713/11558
    ae974a485f413a2113503eed53cd6c53
    10.1007/s40273-019-00864-8
    Scopus Count
    Collections
    UMB Open Access Articles 2019

    entitlement

    Related articles

    • Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    • Authors: Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ
    • Issue date: 2003 Jul 9
    • Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
    • Authors: Nguyen J, Barritt AS 4th, Jhaveri R
    • Issue date: 2019 Apr
    • Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    • Authors: Hartwell D, Jones J, Baxter L, Shepherd J
    • Issue date: 2011 Apr
    • Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
    • Authors: Due OT, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, Chaikledkaew U
    • Issue date: 2020 Sep
    • A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    • Authors: McEwan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J
    • Issue date: 2017 Feb
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.